Physician profile
Michael Hammer
NPI 1508808759
$100,245.94
in general payments reported to CMS, 2019-2025
14 companies · $208 in 2025
The $208 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $16K · 2021: $21K · 2022: $17K · 2023: $3,374 · 2024: $724 · 2025: $208.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,805 · Food and Beverage: $1,152 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,805.00 |
| Food and Beverage | $1,151.69 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $51,918.85 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $29,414.93 | 2019-2023 | Qelbree |
| Ucb, INC. | $16,517.03 | 2019-2025 | Nayzilam, Fintepla, Briviact |
| Livanova USA, INC. | $517.76 | 2019-2021 | |
| Eisai INC. | $492.89 | 2019-2021 | |
| Neurelis, INC. | $449.42 | 2020-2023 | Valtoco |
| Corium, LLC | $285.48 | 2022-2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $240.09 | 2020-2022 | |
| Greenwich Biosciences, INC. | $141.07 | 2019 | |
| Shire North American Group INC | $127.88 | 2019 | |
| Tris Pharma INC | $54.11 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $40.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.20 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $15.82 | 2023 | Fycompa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hammer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.